[
  {
    "ts": null,
    "headline": "Anne Wojcicki Wins Bidding for 23andMe",
    "summary": "Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid.",
    "url": "https://finnhub.io/api/news?id=a4c69cc3a256b60bb09edac181d40da2d2738b8af5d5012bbe5d1706ac145abe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749850920,
      "headline": "Anne Wojcicki Wins Bidding for 23andMe",
      "id": 135259241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron is backing away from buying the DNA-testing company after a nonprofit controlled by co-founder Wojcicki made a higher bid.",
      "url": "https://finnhub.io/api/news?id=a4c69cc3a256b60bb09edac181d40da2d2738b8af5d5012bbe5d1706ac145abe"
    }
  },
  {
    "ts": null,
    "headline": "23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm",
    "summary": "(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction.  Last month, Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and the non-profit TTAM Research Institute.  Once a trailblazer in ancestry DNA testing, 23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in demand and a 2023 data breach that exposed sensitive genetic and personal information of millions of customers.",
    "url": "https://finnhub.io/api/news?id=a627c59d729ef10f998290ac6c107dde4a7d99512f886493fa688ec84c5145ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749846622,
      "headline": "23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm",
      "id": 135259242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction.  Last month, Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and the non-profit TTAM Research Institute.  Once a trailblazer in ancestry DNA testing, 23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in demand and a 2023 data breach that exposed sensitive genetic and personal information of millions of customers.",
      "url": "https://finnhub.io/api/news?id=a627c59d729ef10f998290ac6c107dde4a7d99512f886493fa688ec84c5145ba"
    }
  },
  {
    "ts": null,
    "headline": "23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process",
    "summary": "TTAM Commits to Comply with Company’s Privacy Policy and All Applicable LawsTTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy or Consumer Genome ServicesTransaction Subject to Court ApprovalSAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it",
    "url": "https://finnhub.io/api/news?id=47b8e29f2a41c5562b5a478421ca8139cacc69b34107d50c00c4c1089d2943ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749846120,
      "headline": "23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process",
      "id": 135259243,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TTAM Commits to Comply with Company’s Privacy Policy and All Applicable LawsTTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe’s Privacy Policy or Consumer Genome ServicesTransaction Subject to Court ApprovalSAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it",
      "url": "https://finnhub.io/api/news?id=47b8e29f2a41c5562b5a478421ca8139cacc69b34107d50c00c4c1089d2943ad"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=79cb06e5b0fd3aff8927b02b9005a7b5379fd07f7df774ddfb049d3babc879e1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749833220,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 135432293,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=79cb06e5b0fd3aff8927b02b9005a7b5379fd07f7df774ddfb049d3babc879e1"
    }
  },
  {
    "ts": null,
    "headline": "AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn",
    "summary": "AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns. See why I rate ABCL stock as a Hold.",
    "url": "https://finnhub.io/api/news?id=6930c6ddebbb917db5034e3f8397291c89aa7c39104ae81a9f9563cff11132ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749822312,
      "headline": "AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn",
      "id": 135255427,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1922115813/image_1922115813.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns. See why I rate ABCL stock as a Hold.",
      "url": "https://finnhub.io/api/news?id=6930c6ddebbb917db5034e3f8397291c89aa7c39104ae81a9f9563cff11132ca"
    }
  },
  {
    "ts": null,
    "headline": "These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025",
    "summary": "Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you.",
    "url": "https://finnhub.io/api/news?id=1c24c42115656dcc9178060ddb62b93c3c72ae04ce0122bd0fb2c221cf5022cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749819420,
      "headline": "These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025",
      "id": 135244068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you.",
      "url": "https://finnhub.io/api/news?id=1c24c42115656dcc9178060ddb62b93c3c72ae04ce0122bd0fb2c221cf5022cf"
    }
  }
]